Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

• Authors: Ramy Rahmé, Lionel Ades, Xavier Thomas, Agnès Guerci-Bresler, Arnaud Pigneux, Norbert Vey, Emmanuel Raffoux, Sylvie Castaigne, Olivier Spertini, Sebastian Wittnebel, Jean Pierre Marolleau, Gandhi Damaj, Dominique Bordessoule, Julie Lejeune, Sylvie Chevret, Pierre Fenaux
• Journal: Haematologica (Haematologica) Vol. 103 Issue 11 Pg. e519-e521 (11 2018) ISSN: 1592-8721 [Electronic] Italy
• PMID: 29794147 (Publication Type: Clinical Trial, Letter, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Arsenic Trioxide

Topics

• Aged
• Aged, 80 and over
• Arsenic Trioxide (administration & dosage, adverse effects)
• Disease-Free Survival
• Female
• Humans
• Leukemia, Promyelocytic, Acute (diagnosis, drug therapy, mortality)
• Male
• Survival Rate